Control Strategy
OtherICDs will be implanted in all patients according to current recommendations
NCT Number: NCT06055504
Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
H.C.U de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for SCD prevention in patients with non-ischemic dilated cardiomyopathy with LVEF≤35%
Randomization will be 1:1 and patients are allocated to either control strategy or intervention strategy.
In the control strategy group, patients will get an Implantable Cardioverter Defibrillator (ICD) implanted. Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a Dilated Cardiomyopathy DCM-causing pathogenic or likely pathogenic genetic variants or Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance (CMR). Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ICDs will be implanted in all patients according to current recommendations
Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Time frame: 4 years
Incremental Cost-effectiveness ratio (ICER) of personalized ICD allocation strategy in non-ischemic DCM [ Time Frame: The time horizon of the evaluation will be limited to 4 years ]
The ICER of the personalized ICD allocation strategy compared with standard strategy is defined as the ratio between the variation in costs and the variation in effectiveness between both strategy groups. In the personalized strategy group, costs will include those related to personalization tests (CMR and genetic analysis) plus costs related to implanting and carrying an ICD (in the number of patients who eventually receive a device). In the control group, costs will include only the latter concept. Costs will be measured in Euros. The variation in effectiveness will be measured both in terms of life years gained, measured in years, and in terms of quality of life gained, measured in QALY. In the first case, ICER will be measured as Euros/year; in the second, it will be measured as Euros/QALY.
Time frame: 4 years
Contact information is provided by the study sponsor or research team.
Maria de la Iglesia
CONTACT
Projects Department (CIBER)
CONTACT
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06747429
Cardiovascular Diseases, Heart Diseases
Paris, France
View Trial DetailsNCT04476901
Non-ischemic Dilated Cardiomyopathy
Stanford, California, United States
View Trial DetailsNCT05769036
Arrhythmias, Cardiac, Bundle-Branch Block
Tomsk, Russia
View Trial DetailsNCT05760924
Arrhythmias, Cardiac, Bundle-Branch Block
Tomsk, Russia
View Trial Details